At present, targeted drug development has also made some progress, but only three kinds of drugs (FLT3 inhibitors, IDH2 mutation inhibitors and KMT2A rearrangement inhibitors) targeted at coding gene abnormalities have been recommended by the 2017 European Leukemia Network (ELN), the international expert consensus on the diagnosis and management of adult AML and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines,4, 5 therefore, it is urgent to explore molecular mechanisms of AML and new therapeutic targets to improve clinical prognosis of AML. The gene discussed is IDH2; the disease is acute myeloid leukemia.